Hyderabad based Biopharmaceutical company Suven Life Sciences Ltd. was recently granted product patent bearing no: 7,317,035 by the United States Patent Office. The patent was for a class of a class of selective Serotonin receptor affinity compounds, used in the treatment of neuro-degenerative disorders like Alzheimer’s, Parkinson, schizophrenia and Huntington’s disease. These compounds are being developed into therapeutic agents by Suven. Suven estimates that these drugs once developed will help it tap an $18 billion market. The company has an Indian patent application bearing number 477/MAS/2002 published on 2006-09-15.
This is actually the second product patent that has been granted to Suven in America. The company’s website claims that it has been granted 3 product patents in the European Union and another 4 in India and also the company core area of research is in the area of New Chemical Entities.
For a company with a market cap of just Rs. 410 crores Suven is definitely doing well on the R&D front. Its mid-sized companies like Suven that vindicate India’s decision to upgrade its patent laws to allow for product patents.
This is actually the second product patent that has been granted to Suven in America. The company’s website claims that it has been granted 3 product patents in the European Union and another 4 in India and also the company core area of research is in the area of New Chemical Entities.
For a company with a market cap of just Rs. 410 crores Suven is definitely doing well on the R&D front. Its mid-sized companies like Suven that vindicate India’s decision to upgrade its patent laws to allow for product patents.
